-
1
-
-
44849093562
-
Oncogene addiction
-
discussion 80
-
Weinstein IB, Joe A. Oncogene addiction. Cancer Res. 68, 3077-3080; discussion 80 (2008).
-
(2008)
Cancer Res.
, vol.68
, pp. 3077-3080
-
-
Weinstein, I.B.1
Joe, A.2
-
2
-
-
78649760112
-
Driver mutations and differential sensitivity to targeted therapies: A new approach to the treatment of lung adenocarcinoma
-
Bronte G, Rizzo S, La Paglia L et al. Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat. Rev. 36(Suppl. 3), S21-S29 (2010).
-
(2010)
Cancer Treat. Rev.
, vol.36
, Issue.SUPPL. 3
-
-
Bronte, G.1
Rizzo, S.2
La Paglia, L.3
-
3
-
-
77952965634
-
ALK, lung cancer, and personalized therapy: Portent of the future?
-
Garber K. ALK, lung cancer, and personalized therapy: portent of the future? J. Natl Cancer Inst. 102, 672-675 (2010).
-
(2010)
J. Natl Cancer Inst.
, vol.102
, pp. 672-675
-
-
Garber, K.1
-
4
-
-
79960042770
-
Targeted therapy in non-small-cell lung cancer-is it becoming a reality?
-
Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-small-cell lung cancer-is it becoming a reality? Nat. Rev. Clin. Oncol. 7, 401-414 (2010).
-
(2010)
Nat. Rev. Clin. Oncol.
, vol.7
, pp. 401-414
-
-
Janku, F.1
Stewart, D.J.2
Kurzrock, R.3
-
5
-
-
84859508816
-
ALK translocation and crizotinib in non-small cell lung cancer: An evolving paradigm in oncology drug development
-
Scagliotti G, Stahel RA, Rosell R et al. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development. Eur. J. Cancer 48, 961-973 (2012).
-
(2012)
Eur. J. Cancer
, vol.48
, pp. 961-973
-
-
Scagliotti, G.1
Stahel, R.A.2
Rosell, R.3
-
6
-
-
34547638047
-
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
-
DOI 10.1038/nature05945, PII NATURE05945
-
Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561-566 (2007). (Pubitemid 47206930)
-
(2007)
Nature
, vol.448
, Issue.7153
, pp. 561-566
-
-
Soda, M.1
Choi, Y.L.2
Enomoto, M.3
Takada, S.4
Yamashita, Y.5
Ishikawa, S.6
Fujiwara, S.-I.7
Watanabe, H.8
Kurashina, K.9
Hatanaka, H.10
Bando, M.11
Ohno, S.12
Ishikawa, Y.13
Aburatani, H.14
Niki, T.15
Sohara, Y.16
Sugiyama, Y.17
Mano, H.18
-
7
-
-
34249324494
-
An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms
-
DOI 10.1158/0008-5472.CAN-06-4443
-
Zou HY, Li Q, Lee JH et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive anti-tumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 67, 4408-4417 (2007). (Pubitemid 46815090)
-
(2007)
Cancer Research
, vol.67
, Issue.9
, pp. 4408-4417
-
-
Zou, H.Y.1
Li, Q.2
Lee, J.H.3
Arango, M.E.4
McDonnell, S.R.5
Yamazaki, S.6
Koudriakova, T.B.7
Alton, G.8
Cui, J.J.9
Kung, P.-P.10
Nambu, M.D.11
Los, G.12
Bender, S.L.13
Mroczkowski, B.14
Christensen, J.G.15
-
8
-
-
70350140489
-
Clinical activity observed in a phase i dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066
-
Abstract 3509
-
Kwak EL, Camidge DR, Clark J et al. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. J. Clin. Oncol. 27(Suppl.), Abstract 3509 (2009).
-
(2009)
J. Clin. Oncol.
, vol.27
, Issue.SUPPL.
-
-
Kwak, E.L.1
Camidge, D.R.2
Clark, J.3
-
9
-
-
78049425319
-
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
-
Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010).
-
(2010)
N. Engl. J. Med.
, vol.363
, pp. 1693-1703
-
-
Kwak, E.L.1
Bang, Y.J.2
Camidge, D.R.3
-
10
-
-
80053386829
-
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: A retrospective analysis
-
Shaw AT, Yeap BY, Solomon BJ et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 12, 1004-1012 (2011).
-
(2011)
Lancet Oncol.
, vol.12
, pp. 1004-1012
-
-
Shaw, A.T.1
Yeap, B.Y.2
Solomon, B.J.3
-
11
-
-
84872569905
-
Phase III Study of Crizotinib versus Pemetrexed or Docetaxel Chemotherapy in Patients with advanced ALK-positive Non-Small Cell Lung Cancer (NSCLC) (PROFILE 1007)
-
Abstract LBA1-PR
-
Shaw AT, Kim DW, Nakagawa K et al. Phase III Study of Crizotinib versus Pemetrexed or Docetaxel Chemotherapy in Patients with advanced ALK-positive Non-Small Cell Lung Cancer (NSCLC) (PROFILE 1007). Ann. Oncol. 23(Suppl. 9), Abstract LBA1-PR (2012).
-
(2012)
Ann. Oncol.
, vol.23
, Issue.SUPPL. 9
-
-
Shaw, A.T.1
Kim, D.W.2
Nakagawa, K.3
-
12
-
-
80052969848
-
MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential anti-tumor effects in non-small cell lung cancer according to MET alterations
-
Tanizaki J, Okamoto I, Okamoto K et al. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential anti-tumor effects in non-small cell lung cancer according to MET alterations. J. Thorac. Oncol. 6, 1624-1631 (2011).
-
(2011)
J. Thorac. Oncol.
, vol.6
, pp. 1624-1631
-
-
Tanizaki, J.1
Okamoto, I.2
Okamoto, K.3
-
13
-
-
79955458487
-
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification
-
Ou SH, Kwak EL, Siwak-Tapp C et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J. Thorac. Oncol. 6, 942-946 (2011).
-
(2011)
J. Thorac. Oncol.
, vol.6
, pp. 942-946
-
-
Ou, S.H.1
Kwak, E.L.2
Siwak-Tapp, C.3
-
14
-
-
84862846839
-
Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer
-
Yasuda H, de Figueiredo-Pontes LL, Kobayashi S et al. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J. Thorac. Oncol. 7, 1086-1090 (2012).
-
(2012)
J. Thorac. Oncol.
, vol.7
, pp. 1086-1090
-
-
Yasuda, H.1
De Figueiredo-Pontes, L.L.2
Kobayashi, S.3
-
15
-
-
84863338079
-
ROS1 rearrangements define a unique molecular class of lung cancers
-
Bergethon K, Shaw AT, Ou SH et al. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol. 30, 863-870 (2012).
-
(2012)
J. Clin. Oncol.
, vol.30
, pp. 863-870
-
-
Bergethon, K.1
Shaw, A.T.2
Ou, S.H.3
-
16
-
-
73949092289
-
An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis
-
Zillhardt M, Christensen JG, Lengyel E. An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis. Neoplasia 12, 1-10 (2010).
-
(2010)
Neoplasia
, vol.12
, pp. 1-10
-
-
Zillhardt, M.1
Christensen, J.G.2
Lengyel, E.3
-
17
-
-
84863786449
-
Anti-tumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification
-
Okamoto W, Okamoto I, Arao T et al. Anti-tumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol. Cancer Ther. 11, 1557-1564 (2012).
-
(2012)
Mol. Cancer Ther.
, vol.11
, pp. 1557-1564
-
-
Okamoto, W.1
Okamoto, I.2
Arao, T.3
-
18
-
-
84555190809
-
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib
-
Lennerz JK, Kwak EL, Ackerman A et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J. Clin. Oncol. 29, 4803-4810 (2011).
-
(2011)
J. Clin. Oncol.
, vol.29
, pp. 4803-4810
-
-
Lennerz, J.K.1
Kwak, E.L.2
Ackerman, A.3
-
19
-
-
84862776792
-
HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis
-
Shojaei F, Simmons BH, Lee JH et al. HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis. Cancer Lett. 320, 48-55 (2012).
-
(2012)
Cancer Lett.
, vol.320
, pp. 48-55
-
-
Shojaei, F.1
Simmons, B.H.2
Lee, J.H.3
-
20
-
-
33748286819
-
Integrin-regulated FAK-Src signaling in normal and cancer cells
-
DOI 10.1016/j.ceb.2006.08.011, PII S0955067406001220
-
Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr. Opin. Cell. Biol. 18, 516-523 (2006). (Pubitemid 44332916)
-
(2006)
Current Opinion in Cell Biology
, vol.18
, Issue.5
, pp. 516-523
-
-
Mitra, S.K.1
Schlaepfer, D.D.2
-
21
-
-
71849120012
-
Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification
-
Yoshida T, Okamoto I, Okamoto W et al. Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification. Cancer Sci. 101, 167-172 (2010).
-
(2010)
Cancer Sci.
, vol.101
, pp. 167-172
-
-
Yoshida, T.1
Okamoto, I.2
Okamoto, W.3
-
22
-
-
79551709762
-
Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer
-
Sen B, Peng S, Saigal B et al. Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer. Clin. Cancer Res. 17, 514-524 (2011).
-
(2011)
Clin. Cancer Res.
, vol.17
, pp. 514-524
-
-
Sen, B.1
Peng, S.2
Saigal, B.3
-
23
-
-
42049092982
-
Regulation of Id1 expression by Src: Implications for targeting of the bone morphogenetic protein pathway in cancer
-
DOI 10.1158/0008-5472.CAN-07-6403
-
Gautschi O, Tepper CG, Purnell PR et al. Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer. Cancer Res. 68, 2250-2258 (2008). (Pubitemid 351521798)
-
(2008)
Cancer Research
, vol.68
, Issue.7
, pp. 2250-2258
-
-
Gautschi, O.1
Tepper, C.G.2
Purnell, P.R.3
Izumiya, Y.4
Evans, C.P.5
Green, T.P.6
Desprez, P.Y.7
Lara, P.N.8
Gandara, D.R.9
Mack, P.C.10
Kung, H.-J.11
-
24
-
-
0025238437
-
The protein Id: A negative regulator of helix-loop-helix DNA binding proteins
-
Benezra R, Davis RL, Lockshon D et al. The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell 61, 49-59 (1990).
-
(1990)
Cell
, vol.61
, pp. 49-59
-
-
Benezra, R.1
Davis, R.L.2
Lockshon, D.3
-
25
-
-
79851510244
-
The stem cell gene 'inhibitor of differentiation 1' (ID1) is frequently expressed in non-small cell lung cancer
-
Rothschild SI, Kappeler A, Ratschiller D et al. The stem cell gene 'inhibitor of differentiation 1' (ID1) is frequently expressed in non-small cell lung cancer. Lung Cancer 71, 306-311 (2011).
-
(2011)
Lung Cancer
, vol.71
, pp. 306-311
-
-
Rothschild, S.I.1
Kappeler, A.2
Ratschiller, D.3
-
26
-
-
84866541922
-
MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma
-
Rothschild SI, Tschan MP, Federzoni EA et al. MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma. Oncogene 31, 4221-4232 (2012).
-
(2012)
Oncogene
, vol.31
, pp. 4221-4232
-
-
Rothschild, S.I.1
Tschan, M.P.2
Federzoni, E.A.3
-
27
-
-
84862856363
-
MicroRNA-381 represses ID1 and is deregulated in lung adenocarcinoma
-
Rothschild SI, Tschan MP, Jaggi R et al. MicroRNA-381 represses ID1 and is deregulated in lung adenocarcinoma. J. Thorac. Oncol. 7, 1069-1077 (2012).
-
(2012)
J. Thorac. Oncol.
, vol.7
, pp. 1069-1077
-
-
Rothschild, S.I.1
Tschan, M.P.2
Jaggi, R.3
-
28
-
-
0035710746
-
-ΔΔCT method
-
DOI 10.1006/meth.2001.1262
-
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25, 402-408 (2001). (Pubitemid 34164012)
-
(2001)
Methods
, vol.25
, Issue.4
, pp. 402-408
-
-
Livak, K.J.1
Schmittgen, T.D.2
-
29
-
-
67649396221
-
The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells
-
Purnell PR, Mack PC, Tepper CG et al. The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells. J. Thorac. Oncol. 4(4), 448-454 (2009).
-
(2009)
J. Thorac. Oncol.
, vol.4
, Issue.4
, pp. 448-454
-
-
Purnell, P.R.1
MacK, P.C.2
Tepper, C.G.3
-
30
-
-
84891746435
-
Major partial response to crizotinib a dual MET/ALK inhibitor in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement
-
Kohanka A, Barti-Juhasz H, Schönleber J et al. Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement. Lung Cancer 83(1), 109-111 (2014).
-
(2014)
Lung Cancer
, vol.83
, Issue.1
, pp. 109-111
-
-
Kohanka, A.1
Barti-Juhasz, H.2
Schönleber, J.3
-
31
-
-
0242384942
-
Alternative Splicing of the Human Cyclin D-binding Myb-like Protein (hDMP1) Yields a Truncated Protein Isoform That Alters Macrophage Differentiation Patterns
-
DOI 10.1074/jbc.M307067200
-
Tschan MP, Fischer KM, Fung VS et al. Alternative splicing of the human cyclin D-binding Myb-like protein (hDMP1) yields a truncated protein isoform that alters macrophage differentiation patterns. J. Biol. Chem. 278, 42750-42760 (2003). (Pubitemid 37345884)
-
(2003)
Journal of Biological Chemistry
, vol.278
, Issue.44
, pp. 42750-42760
-
-
Tschan, M.P.1
Fischer, K.M.2
Fung, V.S.3
Pirnia, F.4
Borner, M.M.5
Fey, M.F.6
Tobler, A.7
Torbett, B.E.8
|